By Dr Alex Thompson, Lecturer in sensing in cancer
World Cancer Day provides an opportunity both to celebrate the huge progress that has been made in the fight against cancer and to remember the challenges that lie ahead. While cancer survival has doubled in the UK over the last 40 years, the disease still causes more than one out of every four UK deaths.
By guest blogger Chanice Henry, Editor, Pharma IQ
In the fight against one of the world’s most widespread diseases, new research has found that pharmacists are key in the optimisation of medical treatment for breast cancer patients.
Breast cancer is the most common cancer that occurs in women. In 2012 there were 1.7 million new diagnoses – which equated to 12% of all new cancer cases. Less than one per cent of breast cancer develops in males.
Despite its prevalence, death rates from this form of cancer have been consistently declining over the past 25 years due to better awareness and advancing treatment options.
By Dr Jon Krell, Principal Investigator within the Ovarian Cancer Action Research Centre (OCARC), a collaborative, multi-disciplinary team of clinicians and scientists, focused on translational research to improve outcomes for women with ovarian cancer.
March is Ovarian Cancer Awareness Month, and an opportunity to highlight a key part of our Centre’s research programme aimed at improving early diagnosis and identifying risk factors.
By Gianpaolo Fusari and Madeleine Maxwell at the Helix Centre for Design in Healthcare, a multi-disciplinary team of designers, technologists, researchers and clinicians based at St. Mary’s Hospital, using human-centred design methods to tackle problems in healthcare.
Over 41,000 people are diagnosed with bowel cancer every year in the UK, and at 16,000 deaths per year, it is the second most common cause of cancer death in the UK behind lung cancer.
By Student Challenges Competition 2015/16 Audience Choice Award winners, Antonios Chronopoulos and Tyler Lieberthal
Pancreatic cancer has the lowest survival rate of all major cancers and is widely regarded as a death sentence. The 5-year survival rate is still in the single digits at 3% and this figure has not changed over the past four decades largely due to lack of specific therapies and inability of early detection. Symptoms rarely develop with early disease, which translates to more than 85% of patients receiving their diagnosis at an advanced stage when the tumour is metastatic and no longer treatable. Modern imaging techniques, such as CT and MRI are expensive and unable to detect early-stage lesions.
How will plain packaging influence smoking behaviours?
By Imperial medical students Thomas Hughes and Thomas O’Connor
Today, 17th February 2016, marks the first ever World Cholangiocarcinoma Day.
Cholangiocarcinoma (CCA) is a primary liver cancer, usually formed from glandular structures in the epithelial tissue (adenocarcinomatous). It occurs in the bile ducts and is classed as being either intra-hepatic (IHCC) or extra-hepatic (EHCC) depending on whether the tumour forms inside or outside of the liver.
CCA is the second most common form of primary hepatic malignancies in the world, with survival beyond a year of diagnosis being <5%. It represents 30% of primary hepatic malignancies with a mean survival rate of 3-6 months after diagnosis, due mostly to the late presentation of symptoms which massively reduces treatment success rates.
By Centre for Health Policy Intern Natasha Chainani
A few days ago, the American Cancer Society reported an incidence of 4.3 million cancer cases in China in 2015 alone along with 2.8 million deaths due to cancer.
A few years ago, during my early teens, when I was just learning the ways of the world, I was told I had lost family members to cancer. Throat cancer and pancreatic cancer to be precise.
A few decades ago, the scientific and clinical world was just discovering what cancer was and its capabilities.
And today, 4th February 2016 is World Cancer Day.
By soon to be Imperial medical student, Hannah Lewis
I will start my medical course at Imperial in October 2015 and I was lucky enough to spend 5 months in Gambia at the beginning of the year, gaining insight into medical research in resource-poor settings. It is the smallest country in West Africa, and it is where the British Medical Research Council (MRC) has a big research unit. I worked closely with the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) group, who are looking at the link between hepatitis B and liver cancer.
Initially, I was concerned that, with no previous medical training, I would not be able to learn as much from the experience as fully-fledged medical students.
By Imperial Medical Student, Aisha Chaudry
As part of my gap year placement, I was given the opportunity to be involved in the PROLIFICA study at the Medical Research Council Unit (MRC) in The Gambia.
PROLIFICA is an EC funded project investigating liver cancer, which arises because of cirrhosis (scarring) of the liver, a chronic condition that can stop the liver from functioning.
Having reached my halfway point of my time abroad, I have decided to write a report about my experience so far.
Whilst being at the MRC, I have been able to experience research in both a clinical and laboratory setting.